share_log
Breakings ·  Dec 3 20:00
Terns Pharmaceuticals Announces Positive Early Data From Phase 1 Cardinal Trial of Tern-701 for Chronic Myeloid Leukemia
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment